TLDR
- IONS gains as FDA expands TRYNGOLZA approval for severe triglycerides.
- TRYNGOLZA lowers triglycerides and cuts acute pancreatitis risk sharply.
- Phase 3 CORE studies backed FDA approval with strong clinical results.
- Ionis moves into broader commercial launch with monthly autoinjector drug.
- Shares climbed to $77.10 after volatile trading and late-morning spike.
Ionis Pharmaceuticals gained 1.45% to $77.10 after the FDA expanded TRYNGOLZA approval for severe hypertriglyceridemia. The decision gives adults a new monthly treatment for lowering triglycerides and reducing acute pancreatitis risk. IONS stock briefly moved above $78 before settling higher during afternoon trading.
Ionis Pharmaceuticals, Inc., IONS
FDA Expands TRYNGOLZA Use
The FDA approved TRYNGOLZA as an addition to diet for adults with severe hypertriglyceridemia. The condition involves triglyceride levels of at least 500 milligrams per deciliter. These high levels can sharply increase the risk of acute pancreatitis.
Ionis offers TRYNGOLZA in 50-milligram and 80-milligram doses through a monthly autoinjector. Patients can administer the medicine themselves, which may simplify regular treatment. The expanded approval also broadens the drug’s potential reach beyond rare forms of the condition.
Severe hypertriglyceridemia often remains difficult to control through diet and existing lipid-lowering medicines. Many patients continue facing pancreatitis risk despite treatment and lifestyle changes. Acute attacks can cause severe abdominal pain, long hospital stays, organ damage, and death.
Phase 3 Studies Support Approval
The FDA based its decision on results from the Phase 3 CORE and CORE2 studies. Researchers tested TRYNGOLZA among adults with severe hypertriglyceridemia across both clinical trials. The New England Journal of Medicine published the findings.
TRYNGOLZA lowered fasting triglyceride levels by as much as 72% against placebo after six months. Moreover, patients maintained those reductions through the 12-month assessment period. The medicine also reduced acute pancreatitis events by as much as 91%.
Among patients with complete 12-month data, 86% reduced triglycerides below 500 milligrams per deciliter. That level represents an important threshold for lowering pancreatitis risk. The results showed strong effects among patients with the highest triglyceride levels and previous attacks.
The overall number needed to treat for preventing one pancreatitis episode reached 20 over one year. However, that figure fell to four among the highest-risk patients. This group included patients with triglycerides above 880 milligrams per deciliter and prior pancreatitis.
Approval Strengthens Ionis Commercial Strategy
Ionis reported a favorable safety and tolerability profile across the clinical development program. Injection site reactions and increased liver enzymes ranked among the most common adverse reactions. These reactions occurred at least two percentage points more often than placebo.
The approval marks Ionis’ first independent launch targeting a prevalent disease. Previously, the company established TRYNGOLZA within familial chylomicronemia syndrome, a rare severe hypertriglyceridemia form. The expanded label now opens access to a broader adult population.
Ionis developed TRYNGOLZA as an RNA-targeted medicine that reduces production of apolipoprotein C-III. This protein regulates triglyceride metabolism and contributes to elevated blood triglyceride levels. Lowering its production helps the body clear triglyceride-rich particles more effectively.
IONS stock showed volatile trading following the announcement and climbed sharply during late-morning activity. Shares crossed $78 before losing part of the intraday advance. However, the stock remained 1.45% higher at $77.10 during afternoon trading.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
